Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Autor: Feng, S, Phillips, DJ, White, T, Sayal, H, Aley, PK, Bibi, S, Dold, C, Fuskova, M, Gilbert, SC, Hirsch, I, Humphries, HE, Jepson, B, Kelly, EJ, Plested, E, Shoemaker, K, Thomas, KM, Vekemans, J, Villafana, TL, Lambe, T, Pollard, AJ, Voysey, M, Adlou, S, Allen, L, Angus, B, Anslow, R, Asselin, M-C, Baker, N, Baker, P, Barlow, T, Beveridge, A, Bewley, KR, Brown, P, Brunt, E, Buttigieg, KR, Camara, S, Charlton, S, Chiplin, E, Cicconi, P, Clutterbuck, EA, Collins, AM, Coombes, NS, Clemens, SAC, Davison, M, Demissie, T, Dinesh, T, Douglas, AD, Duncan, CJA, Emary, KRW, Ewer, KJ, Felle, S, Ferreira, DM, Finn, A, Folegatti, PM, Fothergill, R, Fraser, S, Garlant, H, Gatcombe, L, Godwin, KJ, Goodman, AL, Green, CA, Hallis, B, Hart, TC, Heath, PT, Hill, H, Hill, AVS, Jenkin, D, Kasanyinga, M, Kerridge, S, Knight, C, Leung, S, Libri, V, Lillie, PJ, Marinou, S, McGlashan, J, McGregor, AC, McInroy, L, Minassian, AM, Mujadidi, YF, Penn, EJ, Petropoulos, CJ, Pollock, KM, Proud, PC, Provstgaard-Morys, S, Rajapaska, D, Ramasamy, MN, Sanders, K, Shaik, I, Singh, N, Smith, A, Snape, MD, Song, R, Shrestha, S, Sutherland, RK, Thomson, EC, Turner, DPJ, Webb-Bridges, A, Wrin, T, Williams, CJ

Publikováno v: Nature Medicine

The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4f2fd5f45e6c2c0e1c1d6865f6d232
https://pubmed.ncbi.nlm.nih.gov/34588689

Detection of SARS-CoV-2 BA.2.86 by lateral flow devices.

Autor: Bown A; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK. Electronic address: abbie.bown@ukhsa.gov.uk., Sweed A; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Catton M; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Nelthorpe-Cowne J; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Conti-Frith H; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Elderfield R; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Terrey J; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Abib H; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Lui C; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Fisher E; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK., Bewley KR; Vaccine Development and Evaluation Preparedness Division, UK Health Security Agency, Porton Down, UK., Coombes NS; Vaccine Development and Evaluation Preparedness Division, UK Health Security Agency, Porton Down, UK., Robinson D; Product and Delivery, UK Health Security Agency, UK., Agrawal S; Product and Delivery, UK Health Security Agency, UK., Hallis B; Vaccine Development and Evaluation Preparedness Division, UK Health Security Agency, Porton Down, UK., Blandford E; Public Health and Clinical Oversight, Clinical and Public Health Division, UK Health Security Agency, UK., Fowler T; Public Health and Clinical Oversight, Clinical and Public Health Division, UK Health Security Agency, UK., Williamson DA; Specialist Microbiology and Laboratories, UK Health Security Agency, UK., Vipond R; Diagnostic Evaluation and Innovation Group, Diagnostics and Pathogen Characterisation Division, UK Health Security Agency, Porton Down, UK.

Publikováno v: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Feb; Vol. 139, pp. 168-170. Date of Electronic Publication: 2023 Dec 25.

Syrian hamster convalescence from prototype SARS-CoV-2 confers measurable protection against the attenuated disease caused by the Omicron variant.

Autor: Ryan KA; UK Health Security Agency, Salisbury, United Kingdom., Bewley KR; UK Health Security Agency, Salisbury, United Kingdom., Watson RJ; UK Health Security Agency, Salisbury, United Kingdom., Burton C; UK Health Security Agency, Salisbury, United Kingdom., Carnell O; UK Health Security Agency, Salisbury, United Kingdom., Cavell BE; UK Health Security Agency, Salisbury, United Kingdom., Challis A; UK Health Security Agency, Salisbury, United Kingdom., Coombes NS; UK Health Security Agency, Salisbury, United Kingdom., Davies ER; UK Health Security Agency, Salisbury, United Kingdom., Edun-Huges J; UK Health Security Agency, Salisbury, United Kingdom., Emery K; UK Health Security Agency, Salisbury, United Kingdom., Fell R; UK Health Security Agency, Salisbury, United Kingdom., Fotheringham SA; UK Health Security Agency, Salisbury, United Kingdom., Gooch KE; UK Health Security Agency, Salisbury, United Kingdom., Gowan K; UK Health Security Agency, Salisbury, United Kingdom., Handley A; UK Health Security Agency, Salisbury, United Kingdom., Harris DJ; UK Health Security Agency, Salisbury, United Kingdom., Hesp R; UK Health Security Agency, Salisbury, United Kingdom., Hunter L; UK Health Security Agency, Salisbury, United Kingdom., Humphreys R; UK Health Security Agency, Salisbury, United Kingdom., Johnson R; UK Health Security Agency, Salisbury, United Kingdom., Kennard C; UK Health Security Agency, Salisbury, United Kingdom., Knott D; UK Health Security Agency, Salisbury, United Kingdom., Lister S; UK Health Security Agency, Salisbury, United Kingdom., Morley D; UK Health Security Agency, Salisbury, United Kingdom., Ngabo D; UK Health Security Agency, Salisbury, United Kingdom., Osman KL; UK Health Security Agency, Salisbury, United Kingdom., Paterson J; UK Health Security Agency, Salisbury, United Kingdom., Penn EJ; UK Health Security Agency, Salisbury, United Kingdom., Pullan ST; UK Health Security Agency, Salisbury, United Kingdom., Richards KS; UK Health Security Agency, Salisbury, United Kingdom., Summers S; UK Health Security Agency, Salisbury, United Kingdom., Thomas SR; UK Health Security Agency, Salisbury, United Kingdom., Weldon T; UK Health Security Agency, Salisbury, United Kingdom., Wiblin NR; UK Health Security Agency, Salisbury, United Kingdom., Rayner EL; UK Health Security Agency, Salisbury, United Kingdom., Vipond RT; UK Health Security Agency, Salisbury, United Kingdom., Hallis B; UK Health Security Agency, Salisbury, United Kingdom., Salguero FJ; UK Health Security Agency, Salisbury, United Kingdom., Funnell SGP; UK Health Security Agency, Salisbury, United Kingdom., Hall Y; UK Health Security Agency, Salisbury, United Kingdom.

Publikováno v: PLoS pathogens [PLoS Pathog] 2023 Apr 04; Vol. 19 (4), pp. e1011293. Date of Electronic Publication: 2023 Apr 04 (Print Publication: 2023).

Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents.

Autor: Coombes NS; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Bewley KR; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Le Duff Y; Division of Infectious Disease Diagnostics, National Institute for Biological Standards, Medicines and Healthcare Products Regulatory Agency, Potters Bar EN6 3QG, UK., Hurley M; Division of Infectious Disease Diagnostics, National Institute for Biological Standards, Medicines and Healthcare Products Regulatory Agency, Potters Bar EN6 3QG, UK., Smith LJ; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Weldon TM; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Osman K; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Pullan S; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Berry N; Division of Infectious Disease Diagnostics, National Institute for Biological Standards, Medicines and Healthcare Products Regulatory Agency, Potters Bar EN6 3QG, UK., Hallis B; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Charlton S; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Hall Y; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK., Funnell SGP; Medical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.

Publikováno v: Viruses [Viruses] 2023 Feb 25; Vol. 15 (3). Date of Electronic Publication: 2023 Feb 25.

Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever.

Autor: Clay KA; Academic Department, Royal Centre for Defence Medicine (Academia and Research), Birmingham, United Kingdom.; CBR Division, Defence Science and Technology Laboratorygrid.417845.b (Dstl), Porton Down, Salisbury, Wiltshire, United Kingdom., Hartley MG; CBR Division, Defence Science and Technology Laboratorygrid.417845.b (Dstl), Porton Down, Salisbury, Wiltshire, United Kingdom., Armstrong S; CBR Division, Defence Science and Technology Laboratorygrid.417845.b (Dstl), Porton Down, Salisbury, Wiltshire, United Kingdom., Bewley KR; Public Health Englandgrid.271308.f, Porton Down, Salisbury, Wiltshire, United Kingdom., Godwin K; Public Health Englandgrid.271308.f, Porton Down, Salisbury, Wiltshire, United Kingdom., Rayner E; Public Health Englandgrid.271308.f, Porton Down, Salisbury, Wiltshire, United Kingdom., Vipond J; Public Health Englandgrid.271308.f, Porton Down, Salisbury, Wiltshire, United Kingdom., Bailey M; Academic Department, Royal Centre for Defence Medicine (Academia and Research), Birmingham, United Kingdom., Atkins TP; CBR Division, Defence Science and Technology Laboratorygrid.417845.b (Dstl), Porton Down, Salisbury, Wiltshire, United Kingdom.; College of Life and Environmental Sciences, University of Exeter, Exeter, United Kingdom., Norville IH; CBR Division, Defence Science and Technology Laboratorygrid.417845.b (Dstl), Porton Down, Salisbury, Wiltshire, United Kingdom.

Publikováno v: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2021 Oct 18; Vol. 65 (11), pp. e0067321. Date of Electronic Publication: 2021 Aug 09.